Literature DB >> 35577571

Clinical Reasoning: A 48-year-old Woman With 6 Months of Vivid Visual Hallucinations.

Jennifer Kizza1, Richard J Lu1, Jonah Zuflacht2, Marc Bouffard1.   

Abstract

Visual hallucinations are frequently encountered in clinical practice. It is critical for neurologists, particularly those in training, to develop a systematic approach for evaluating patients presenting with such unique and often perplexing symptoms. Here, we present the case of a 48-year-old woman who developed vivid visual hallucinations after receiving nivolumab for melanoma. We discuss the broad differential diagnosis for visual hallucinations and how the history and examination can guide one's evaluation.
© 2022 by The American College of Gastroenterology.

Entities:  

Year:  2022        PMID: 35577571      PMCID: PMC9421773          DOI: 10.1212/WNL.0000000000200806

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   11.800


  10 in total

1.  Immune Checkpoint Inhibitor-Associated Optic Neuritis.

Authors:  Jasmine H Francis; Korey Jaben; Bianca D Santomasso; Julia Canestraro; David H Abramson; Paul B Chapman; Meghan Berkenstock; Mary E Aronow
Journal:  Ophthalmology       Date:  2020-05-08       Impact factor: 12.079

Review 2.  The Charles Bonnet Syndrome: a Systematic Review of Diagnostic Criteria.

Authors:  Ali G Hamedani; Victoria S Pelak
Journal:  Curr Treat Options Neurol       Date:  2019-07-25       Impact factor: 3.598

3.  A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.

Authors:  R W Beck; P A Cleary; M M Anderson; J L Keltner; W T Shults; D I Kaufman; E G Buckley; J J Corbett; M J Kupersmith; N R Miller
Journal:  N Engl J Med       Date:  1992-02-27       Impact factor: 91.245

Review 4.  Optic Neuritis.

Authors:  Jeffrey L Bennett
Journal:  Continuum (Minneap Minn)       Date:  2019-10

5.  Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder.

Authors:  John J Chen; Eoin P Flanagan; M Tariq Bhatti; Jiraporn Jitprapaikulsan; Divyanshu Dubey; Alfonso Sebastian S Lopez Chiriboga; James P Fryer; Brian G Weinshenker; Andrew McKeon; Jan-Mendelt Tillema; Vanda A Lennon; Claudia F Lucchinetti; Amy Kunchok; Collin M McClelland; Michael S Lee; Jeffrey L Bennett; Victoria S Pelak; Gregory Van Stavern; Ore-Ofe O Adesina; Eric R Eggenberger; Marie D Acierno; Dean M Wingerchuk; Byron L Lam; Heather Moss; Shannon Beres; Aubrey L Gilbert; Veeral Shah; Grayson Armstrong; Gena Heidary; Dean M Cestari; Hadas Stiebel-Kalish; Sean J Pittock
Journal:  Neurology       Date:  2020-06-17       Impact factor: 11.800

6.  Optic neuropathy associated with systemic sarcoidosis.

Authors:  Desmond P Kidd; Ben J Burton; Elizabeth M Graham; Gordon T Plant
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-08-02

Review 7.  Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review.

Authors:  Caberry W Yu; Matthew Yau; Natalie Mezey; Ishraq Joarder; Jonathan A Micieli
Journal:  Eye Brain       Date:  2020-11-03

Review 8.  Central Nervous System Demyelination Associated With Immune Checkpoint Inhibitors: Review of the Literature.

Authors:  Marcos C B Oliveira; Marcelo H de Brito; Mateus M Simabukuro
Journal:  Front Neurol       Date:  2020-12-11       Impact factor: 4.003

9.  Negative outcome Charles Bonnet syndrome.

Authors:  Thomas M Cox; Dominic H ffytche
Journal:  Br J Ophthalmol       Date:  2014-05-13       Impact factor: 4.638

Review 10.  Hallucinations Experienced by Visually Impaired: Charles Bonnet Syndrome.

Authors:  Linda Pang
Journal:  Optom Vis Sci       Date:  2016-12       Impact factor: 1.973

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.